GlassScriptPhysician profile
Lewis Gamarra
NPI 1124048608
$1,650.81
in general payments reported to CMS, 2019-2025
15 companies · $396 in 2025
The $396 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $99.41 · 2021: $413 · 2022: $113 · 2023: $329 · 2024: $85.89 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $288.87 | 2020-2024 | Xarelto |
| Eisai INC. | $278.77 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.12 | 2019-2023 | Andexxa |
| Novo Nordisk INC | $178.21 | 2022-2025 | Ozempic |
| Collegium Pharmaceutical, INC. | $121.69 | 2019-2023 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.70 | 2019-2023 | Relistor |
| Glaxosmithkline, LLC. | $116.35 | 2021 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Pfizer INC. | $63.18 | 2019 | |
| Mylan Specialty L.P. | $46.81 | 2019-2020 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Exact Sciences Corporation | $27.71 | 2025 | The Cologuard Plus Collection Kit |
| Apria Healthcare LLC | $20.58 | 2021 | |
| Irhythm Technologies, INC. | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Gamarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.